INNOVIVE Pharmaceuticals Announces Scientific Advisory Board Additions.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- INNOVIVE Pharmaceuticals, Inc., a Manhattan-based biopharmaceutical company, announced today that Alan F. List, M.D., and Howard I. Scher, M.D., two of the nation's leading oncology experts, have joined its Scientific Advisory Board. "The addition of these leading clinicians further strengthens our already robust Scientific Advisory Board and provides INNOVIVE with additional assets to develop our growing oncology pipeline," said Steven Kelly, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , INNOVIVE Pharmaceuticals, Inc. The new members of INNOVIVE's Scientific Advisory Board are as follows: Alan F. List, M.D., Chief of the Hematologic hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. Division at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, and Professor of Medicine and Oncology at the University of South Florida College of Medicine As of Fall 2006, there were 477 students in the M.D. program; 78 students in the M.S. and 83 students in the Ph.D. program in the School of Basic Biomedical Sciences; and 55 students in the DPT program in the School of Physical Therapy. . Dr. List is an internationally recognized investigator in the biology and treatment of acute myeloid leukemia (AML AML - A Manufacturing Language ) and myelodysplastic syndrome (MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there ). He serves on the Board of Directors for the MDS Foundation and the Aplastic Anemia and MDS International Foundation. Howard I. Scher, M.D., Chief of the Genitourinary genitourinary /gen·i·to·uri·nary/ (jen?i-to-u´ri-nar-e) pertaining to the genital and urinary organs. gen·i·to·u·ri·nar·y adj. Abbr. Oncology Service and the D. Wayne Calloway Wayne Calloway was chairman and CEO of PepsiCo from 1986 until the mid 1990s. He was chairman of the board of Wake Forest University. They named their undergraduate school of business in his honor in 1995. He died July 8, 1998 from cancer. Chair in Urologic Oncology at Memorial Sloan Kettering Cancer Center, New York, where he oversees development of new therapies for prostate cancer, including the use of monoclonal antibodies, vaccines, and drugs that target specific signaling pathways. Dr. Scher is widely renowned in the field of genitourinary cancers. Other members of the INNOVIVE Pharmaceuticals Scientific Advisory Board include Peter Anthony Jones, Ph.D., Director of the USC/Norris Comprehensive Cancer Center and Distinguished Professor of Urology, Biochemistry and Molecular Biology, Keck School of Medicine at the University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission ; Edward A. Sausville, M.D., Ph.D., Associate Director for Clinical Research, Greenebaum Cancer Center, University of Maryland University of Maryland can refer to:
Innovive Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in New York, N.Y. The company's mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. For additional information visit www.innovivepharma.com. This press release contains forward-looking statements that involve risks and uncertainties that could cause INNOVIVE's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of INNOVIVE's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of INNOVIVE's product candidates, the risk that the results of clinical trials may not support INNOVIVE's claims, INNOVIVE's reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. INNOVIVE assumes no obligation to update these forward-looking statements, except as required by law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion